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ABSTRACT 
Topiramate is a new antiepileptic drug (AED) that has been approved worldwide (in more than 80 countries) for the treatment of 
various kinds of epilepsy. It is currently being evaluated for its effect in various neurological and psychiatric disorders. Topiramate 
is used alone or with other medications to prevent and control seizures (epilepsy). This medication is also used to prevent migraine 
headaches and decrease how often you get them. The present review includes all available information like pharmacokinetics, 
pharmacological action and side effects. Moreover sometimes it is necessary to monitor the therapeutic concentration of Topiramate. 
The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral 
clearance (22-36 mL/min), which, in immunotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and 
a long half-life (19-25 hours), which is reduced when co administered with inducing AEDs such as phenytoin, phenobarbital and 
carbamazepine. This paper provides a critical review of the pharmacokinetic interactions of topiramate with old and new AEDs, an 
oral contraceptive, and the CNS-active drugs lithium, haloperidol, amitriptyline, risperidone, sumatriptan, propranolol and 
dihydroergotamine. The results of many of these drug interaction studies with topiramate have not been published before, and are 
presented and discussed for the first time in this article. 
Keywords: Antiepileptic drug, bipolar disorder, epilepsy, migraine, obesity, seizures, substance abuse, topiramate, weight loss. 
 
Article Info: Received 22 March 2017; Review Completed 02 April 2017; Accepted 02 April 2017, Available online 15 May 2017 
Cite this article as: 
Singh A, Singh P, Patel CK, Benefit of Topiramate in the treatment of symptoms of borderline personality 
disorder: a typical review, Journal of Drug Delivery and Therapeutics. 2017; 7(3):1-7                                
DOI: http://dx.doi.org/10.22270/jddt.v7i3.1433  
*Address for Correspondence  
Asheesh Singh, Senior Research Scientist, Department of Analytical and Medicinal Chemistry, VNS Institute 
of Pharmacy, Neelbud, Bhopal-462044, (B) 91 07566553683 |+91-9893737249 
Email: asheesh_parihar@yahoo.com 
 
 
INTRODUCTION 
Topiramate (brand name Topamax) is an anticonvulsant 
(antiepilepsy) drug. In late 2012, topiramate was 
approved by the United States Food and Drug 
Administration (FDA) in combination with phentermine 
for weight loss. The drug had previously been used off-
label for this purpose
1-2
.Topiramate was originally 
produced by Ortho-McNeil Neurologics and Noramco, 
Inc., both divisions of the Johnson & Johnson 
Corporation. This medication was discovered in 1979 by 
Bruce E. Maryanoff and Joseph F. Gardocki during their 
research work at McNeil Pharmaceutical. Generic 
versions are available in Canada and were FDA 
approved in September 2006. Mylan Pharmaceuticals 
was recently granted final approval for generic 
topiramate 25, 100, and 200 mg tablets and sprinkle 
capsules by the FDA for sale in the US. 50 mg tablets 
were granted tentative approval. The last patent for 
topiramate in the U.S. was for pediatric use; this patent 
expired on February 28, 2009.5 On May 21, 2010, 
Ortho-McNeil plead guilty and was fined US$6.14 
million by the FDA for promoting Topamax to treat 
psychiatric disorders, without applying for any approval 
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and there was no data from any well-controlled clinical 
trial to demonstrate that Topamax was safe and effective 
to treat any psychiatric conditions
3-5
. 
Topiramate is used to treat epilepsy in children and 
adults, and it was originally used as an anticonvulsant. In 
children, it is indicated for the treatment of Lennox-
Gastaut syndrome, a disorder that causes seizures and 
developmental delay. It is also Food and Drug 
Administration (FDA) approved for, and most frequently 
prescribed for, the prevention of migraines. The drug is 
also used to treat migraines due to the effect it has on the 
blood vessels in the brain. It has been found to be 
increasingly effective for migraine sufferers with limited 
side effects
6-7
. 
Psychiatrists have used topiramate to treat bipolar 
disorder, although the available evidence does not 
support its use in any phase of bipolar disorder 
treatment. A more recent review, published in 2010, 
suggested a benefit of topiramate in the treatment of 
symptoms of borderline personality disorder, however 
the authors note that this was based only on one 
randomized controlled trial and requires replication. 
Also the authors noted that the long-term effects have 
not been studied
8
.
 
Recent clinical reports indicate that it may have mood 
stabilizing properties. Other off-label and investigational 
uses of topiramate include the treatment of essential 
tremor, bulimia nervosa, obsessive-compulsive disorder, 
idiopathic intracranial hypertension and cluster 
headache. Topiramate has not been shown to work as a 
pain medicine in diabetic neuropathy, the only 
neuropathic condition in which it has been adequately 
tested. Dispensing errors have been reported between 
Topamax (topiramate) tablets and Toprol-XL 
(metoprolol succinate) extended-release tablets thereby 
requiring extra care to ensure the correct medication is 
being taken
9-12
. 
Half-life: 19 to 23 hours. The mean elimination half-life 
was 31 hours following repeat administration of the 
extended-release formulation.  
Brand Names  
a. Topamax  
b. Trokendi XR  
c. Topiragen  
d. Qudexy XR  
HETEROCYCLIC CHEMISTRY 
Topiramate is a Sulphamate-substituted monosaccharide 
with a structure distinct from other AEDS. Its chemical 
formula is 2, 3:4, 5-di-O-(l-isopropylidene)-ß-D 
fructopyranosesulphamate. It is a derivative 
of the naturally-occurring monosaccharide D-fructose.  
Topiramate has the molecular formula 
C12H21NO8S. It is of Synthetic origin and belongs to 
Sulphamate Monosaccharides. . The Molecular Weight 
of Topiramate is 339.40
13-14
. 
 
PHARMACEUTICAL ASPECTS 
Solubility 
Topiramate is a white crystalline powder with a bitter 
taste. Topiramate is most soluble in alkaline solutions 
containing sodium hydroxide or sodium phosphate and 
having a pH of 9 to 10. It is freely soluble in acetone, 
chloroform, dimethyl sulfoxide, and ethanol. The 
solubility in water is 9.8 mg/mL. Its saturated solution 
has a pH of 6.3. 
Structure of Topiramate: 
 
2, 3:4, 5-Bis-O-(1-methylethylidene)-β-D-
fructopyranose sulfamate 
Mechanism of Action 
Topiramate is Soluble in most alkaline solutions 
containing sodium hydroxide or sodium phosphate and 
having pH of 9-10. It is freely soluble in acetone, 
chloroform, dimethyl, sulfoxide and ethanol. The precise 
mechanism of action of topiramate is not known. 
However, studies have shown that topiramate blocks the 
action potentials elicited repetitively by a sustained 
depolarization of the neurons in a time-dependent 
manner, suggesting a state-dependent sodium channel 
blocking action. Topiramate also augments the activity 
of the neurotransmitter gamma-aminobutyrate (GABA) 
at some subtypes of the GABAA receptor (controls an 
integral chloride channel), indicating a possible 
mechanism through potentiation of the activity of 
GABA
15-17
. Topiramate also demonstrates antagonism of 
the AMPA/kainate subtype of the glutamate excitatory 
amino acid receptor. It also inhibits carbonic anhydrase 
(particularly isozymes II and IV), but this action is weak 
and unlikely to be related to its anticonvulsant actions
18
. 
Topiramate Drug-Drug Interactions 
Topiramate has many drug-drug interactions. Some of 
the most common are listed below: 
 As topiramate inhibits carbonic anhydrase, use with 
other inhibitors of carbonic anhydrase (e.g. 
acetazolamide) increases the risk of kidney stones. 
 Enzyme inducers (e.g. carbamazepine) can increase 
the elimination of topiramate, possibly necessitating 
dose escalations of topiramate. 
 Topiramate may increase the plasma-levels of 
phenytoin. 
 Topiramate itself is a weak inhibitor of CYP2C19 
and induces CYP3A4; a decrease in plasma levels 
of estrogens and digoxin has been noted during 
topiramate therapy. This can reduce the 
effectiveness of oral contraceptives (birth control 
pills); use of alternative birth control methods is 
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recommended. Neither intrauterine devices (IUDs) 
nor Depo-Provera are affected by topiramate. 
 Alcohol may cause increased sedation or 
drowsiness, and increase the risk of having a 
seizure. 
 As listed in the 06/29/2005 label posted at the 
Drugs@FDA website page 14,'conditions or 
therapies that predispose to acidosis may be additive 
to the bicarbonate lowering effects of Topiramate. 
 Oligohidrosis and hyperthermia were reported in 
post-marketing reports about topiramate; 
antimuscarinic drugs (like trospium) can aggravate 
these disorders
19-20
. 
Pharmacology 
Chemically, topiramate is a sulfamate-substituted 
monosaccharide, related to fructose, a rather unusual 
chemical structure for an anticonvulsant. Topiramate is 
quickly absorbed after oral use. Most of the drug (70%) 
is excreted in the urine unchanged. The remainder is 
extensively metabolized by hydroxylation, hydrolysis, 
and glucuronidation. Six metabolites have been 
identified in humans, none of which constitutes more 
than 5% of an administered dose. 
Several cellular targets have been proposed to be 
relevant to the therapeutic activity of topiramate. These 
include (1) voltage-gated sodium channels; (2) high-
voltage-activated calcium channels; (3) GABA-A 
receptors; (4) AMPA/kainate receptors; and (5) carbonic 
anhydrase isoenzymes. There is evidence that topiramate 
may alter the activity of its targets by modifying their 
phosphorylation state instead of by a direct action. The 
effect on sodium channels could be of particular 
relevance for seizure protection. Although topiramate 
does inhibit high-voltage-activated calcium channels, the 
relevance to clinical activity is uncertain. Effects on 
specific GABA-A receptor isoforms could also 
contribute to the antiseizure activity of the drug. 
Topiramate selectively inhibits cytosolic (type II) and 
membrane associated (type IV) forms of carbonic 
anhydrase. The action on carbonic anhydrase 
isoenzymes may contribute to the drug’s side-effects, 
including its propensity to cause metabolic acidosis and 
calcium phosphate kidney stones. Topiramate inhibits 
maximal electroshock and pentylenetetrazol-induced 
seizures as well as partial and secondarily generalized 
tonic-clonic seizures in the kindling model, findings 
predictive of a broad spectrum of activities clinically. Its 
action on mitochondrial permeability transition pores 
has been proposed as a mechanism
21-22
. 
While many anticonvulsants have been associated with 
apoptosis in young animals, animal experiments have 
found that topiramate is the only anticonvulsant that 
does not induce apoptosis in young animals at doses 
needed to produce an anticonvulsant effect
23
. 
PHARMACOKINETICS AND METABOLISM 
OF TOPIRAMATE 
The pharmacokinetics and pharmacokinetic interactions 
of topiramate (TPM) in humans have been studied quite 
extensively. Topiramate is rapidly absorbed, with a high 
bioavailability that is not affected by concomitant food 
intake. The volume of distribution is 0.6-0.8 l/kg, 
suggesting distribution into total body water. The 
binding of TPM to serum proteins is low, which 
precludes the displacement interactions that are seen 
between highly bound drugs such as valproate and 
phenytoin. The elimination kinetics of TPM are strictly 
linear and, accordingly, there is a linear relationship 
between maintenance dose and steady-state plasma 
levels. Topiramate is excreted predominantly by the 
kidneys as unmetabolized drug. This is generally 
associated with lower interpatient variability in 
elimination kinetics. Approximately 20% of orally 
administered TPM is metabolized in the liver and this 
fraction may increase up to 50% in the presence of 
enzyme-inducing drugs, such as phenytoin or 
carbamazepine. During chronic ingestion of TPM, there 
is no clinically significant accumulation of any active 
metabolite, even in patients taking enzyme-inducing 
drugs. The elimination half-life of TPM is relatively 
long and does not require more frequent than twice-daily 
dosing. Finally, TPM has a relatively low potential for 
drug interactions. The clinically significant 
pharmacokinetic interactions between TPM and other 
antiepileptic drugs are limited to an increase in the 
clearance of TPM when inducing drugs such as 
phenytoin or carbamazepine are added. TPM has little or 
no effect on the pharmacokinetics of other antiepileptic 
drugs, but it can increase the clearance of the estrogenic 
component of oral contraceptives by up to 30%
24-25
. 
The absolute bioavailability, or oral availability, of 
topiramate is 81-95% and is not affected by food. 
Although topiramate is not extensively metabolised 
when administered in monotherapy (fraction 
metabolised approximately 20%), its metabolism is 
induced during polytherapy with carbamazepine and 
phenytoin, and, consequently, its fraction metabolised 
increases. During concomitant treatment with topiramate 
and carbamazepine or phenytoin, the (oral) clearance of 
topiramate increases 2-fold and its half-life becomes 
shorter by approximately 50%, which may require 
topiramate dosage adjustment when phenytoin or 
carbamazepine therapy is added or discontinued. From a 
pharmacokinetic standpoint, topiramate is a unique 
example of a drug that, because of its major renal 
elimination component, is not subject to drug interaction 
due to enzyme inhibition, but nevertheless is susceptible 
to clinically relevant drug interactions due to induction 
of its metabolism. Unlike old AEDs such as phenytoin 
and carbamazepine, topiramate is a mild inducer and, 
currently, the only interaction observed as a result of 
induction by topiramate is that with ethinylestradiol. 
Topiramate only increases the oral clearance of 
ethinylestradiol in an oral contraceptive at high dosages 
(>200 mg/day). Because of this dose-dependency, 
possible interactions between topiramate and oral 
contraceptives should be assessed according to the 
topiramate dosage utilized
26
. 
POSSIBLE SIDE EFFECTS OF TOPIRAMATE: 
All medicines may cause side effects, but many people 
have no, or minor, side effects. Check with your doctor 
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if any of these most COMMON side effects persist or 
become bothersome: 
Constipation; diarrhea; dizziness; drowsiness; dry 
mouth; flushing; headache; loss of appetite; nausea; 
nervousness; stomach pain or upset; symptoms of upper 
respiratory tract infection (eg, cough, mild sore throat, 
running or stuffy nose, sneezing); taste changes; 
tiredness; trouble sleeping; weakness; weight loss. 
Nervous system:  
The majorities of cognitive-related adverse events were 
mild to moderate in severity and frequently occurred in 
isolation. Rapid titration rate and higher initial doses 
were associated with higher incidences of cognitive-
related adverse events.  
Very common (10% or more): Paresthesia, somnolence, 
dizziness. 
Common (1% to 10%): Disturbance in attention, 
memory impairment, amnesia, cognitive disorder, 
mental impairment, psychomotor skills impaired, 
convulsion, coordination abnormal, tremor, lethargy, 
hypothesia, nystagmus, dysgeusia, balance disorder, 
dysarthria, intention tremor, sedation  
Uncommon (0.1% to 1%): Depressed level of 
consciousness, grand mal convulsion, visual field defect, 
complex partial seizures, speech disorder, psychomotor 
hyperactivity, syncope, sensory disturbance, drooling, 
hypersomnia, aphasia, repetitive speech, hypokinesia, 
dyskinesia, dizziness postural, poor quality sleep, 
burning sensation, sensory loss, parosmia, cerebellar 
syndrome, dysesthesia, hypogeusia, stupor, clumsiness, 
aura, ageusia, dysgraphia, dysphasia, neuropathy 
peripheral, presyncope, dystonia, formication  
Rare (less than 0.1%): Apraxia, circadian rhythm sleep 
disorder, hyperesthesia, hyposmia, anosmia, essential 
tremor, akinesia, unresponsive to stimuli. 
Hepatic: Rare (less than 0.1%): Hepatitis, hepatic 
failure, increase in liver enzymes 
Ocular: The primary treatment of cases of secondary 
angle closure glaucoma cause by topiramate is 
discontinuation of the drug. 
Common (1% to 10%): Vision blurred, diplopia, visual 
disturbance 
Uncommon (0.1% to 1%): Visual acuity reduced, 
scotoma, myopia, abnormal sensation in eye, dry eye, 
photophobia, blepharospasm, lacrimation increased, 
photopsia, mydriasis, presbyopia 
Rare (less than 0.1%): Blindness unilateral, blindness 
transient, glaucoma, accommodation disorder, altered 
visual depth perception, scintillating scotoma, eyelid 
edema, night blindness, amblyopia 
Very rare (less than 0.01%): Frequency not reported: 
Angle closure glaucoma, maculopathy, eye movement 
disorder. 
Gastrointestinal:        
Very common (10% or more): Nausea, diarrhea 
Common (1% to 10%): Vomiting, constipation, 
abdominal pain upper, dyspepsia, abdominal pain, dry 
mouth, stomach discomfort, paresthesia oral, gastritis, 
abdominal discomfort 
Uncommon (0.1% to 1%): Pancreatitis, flatulence, 
gastroesophageal reflux disease, abdominal pain lower, 
hypoesthesia oral, gingival bleeding, abdominal 
distension, epigastric discomfort, abdominal tenderness, 
salivary hypersecretion, oral pain, breath odor, 
glossodynia. 
Cardiovascular: Uncommon (0.1% to 1%): 
Bradycardia, sinus bradycardia, palpitations, 
hypotension, orthostatic hypotension, flushing, hot 
flushes Rare (less than 0.1%): Raynaud's phenomenon. 
 Hematologic:  
Common (1% to 10%): Anemia, epistaxis 
Uncommon (0.1% to 1%): Leucopenia, 
thrombocytopenia lymphadenopathy, white blood cell 
count decreased eosinophilia. 
Rare (less than 0.1%): Neutropenia.  
Metabolic: Very common (10% or more): Weight 
decreased 
Common (1% to 10%): Anorexia, decreased appetite, 
weight increased.                                         .   
Uncommon (0.1% to 1%): Metabolic acidosis, 
hypokalemia, increased appetite, polydipsia 
Rare (less than 0.1%): Acidosis hyperchloremic, blood 
bicarbonate decreased. 
Musculoskeletal:  
Common (1% to 10%): Arthralgia, muscle spasms, 
myalgia, muscle twitching, muscular weakness, 
musculoskeletal chest pain 
Uncommon (0.1% to 1%): Joint swelling, 
musculoskeletal stiffness, flank pain, muscle fatigue 
Rare (less than 0.1%): Limb discomfort. 
Psychiatric: Depression and mood problems were dose 
related. 
Psychiatric side effects including insomnia, personality 
disorder, impotence, hallucination, euphoria, psychosis, 
decreased libido, anxiety, depression, mood problems, 
and suicide attempts have been reported. Two cases of 
panic attacks have also been reported. 
Genitourinary: Uncommon (0.1% to 1%): Erectile 
dysfunction, sexual dysfunction, crystal urine present, 
intermenstrual bleeding, leucorrhea, menorrhagia, 
vaginitis, and amenorrhea., urinary tract infections, 
micturition frequency, urinary incontinence, dysuria. 
Respiratory: Respiratory side effects including 
pulmonary embolism, coughing, pneumonia, asthma, 
and bronchitis have been reported. 
Dermatologic:  
Common (1% to 10%): Alopecia, rash, pruritus 
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Uncommon (0.1% to 1%): Anhidrosis, hypoesthesia 
facial, urticaria, erythema, pruritus generalized, rash 
macular, skin discoloration, dermatitis allergic, swelling 
face. 
Rare (less than 0.1%): Stevens-Johnson syndrome, 
erythema multiforme, skin odor abnormal, periorbital 
edema, urticaria localized. 
Others: Very common (10% or more): Fatigue 
Renal: Renal side effects including kidney stones (1.3% 
to 1.5%) and renal tubular acidosis have been reported. 
Hypersensitivity: Common (1% to 10%): 
Hypersensitivity Frequency not reported: Allergic 
edema, conjunctival edema
27-28
. 
IMPORTANT SAFETY INFORMATION 
ABOUT TOPIRAMATE 
a) Topiramate may cause drowsiness, dizziness, 
confusion, trouble concentrating, or vision changes. 
These effects may be worse if you take it with 
alcohol or certain medicines. Use topiramate with 
caution. Do not drive or perform other possibly 
unsafe tasks until you know how you react to it. 
b) Do not change your dose without checking with your 
doctor. 
c) Do not drink alcohol while you take topiramate. 
d) Check with your doctor before you use medicines 
that may cause drowsiness (eg, sleep aids, muscle 
relaxers) while you are taking topiramate; it may add 
to their effects. Ask your pharmacist if you have 
questions about which medicines may cause 
drowsiness. 
e) Topiramate may reduce sweating, which could raise 
body temperature, especially in children. This risk is 
greater in hot weather and/or during vigorous 
exercise. Drink plenty of fluids. Dress lightly in hot 
climates or when exercising. Check carefully for 
signs of decreased sweating. If this occurs, promptly 
seek cooler or air-conditioned shelter and/or stop 
exercising. Seek medical attention right away if you 
have decreased sweating, fever, mental or mood 
changes, headache, or dizziness. 
f) Topiramate may cause high blood acid levels 
(metabolic acidosis). The risk may be greater in 
children and in patients with kidney problems, severe 
breathing problems, or diarrhea. It may also be 
greater in patients who are taking certain other 
medicines (eg, acetazolamide), will be having 
surgery, or are on a ketogenic diet. Over a period of 
time, metabolic acidosis may cause kidney stones, 
bone problems, or decreased growth in children. 
Contact your doctor immediately if you experience 
fast breathing, unusual tiredness or weakness, 
sluggishness, persistent loss of appetite, or fast or 
irregular heartbeat. 
g) Topiramate may cause high blood ammonia levels 
(hyperammonemia). This risk may be greater in 
patients with metabolism problems or certain liver 
problems. It may also be greater in patients who are 
taking valproic acid. Contact your doctor 
immediately if you experience decreased alertness, 
mental changes, sluggishness, unusual tiredness, or 
vomiting. 
h) Patients who take topiramate may be at increased risk 
of suicidal thoughts or actions. The risk may be 
greater in patients who have had suicidal thoughts or 
actions in the past. Watch patients who take 
topiramate closely. Contact the doctor at once if new, 
worsened, or sudden symptoms such as depressed 
mood; anxious, restless, or irritable behavior; panic 
attacks; or any unusual change in mood or behavior 
occur. Contact the doctor right away if any signs of 
suicidal thoughts or actions occur. 
i) Topiramate may cause serious eye problems that 
could lead to permanent loss of vision if not treated. 
Seek medical attention right away if you experience 
new eye symptoms (eg, blurred vision or other vision 
changes, eye pain or redness). 
j) Caution is advised when using topiramate in 
Children; they may be more sensitive to its effects, 
especially decreased sweating and decreased 
bicarbonate levels. 
k) Topiramate may affect growth rate in Children and 
teenagers in some cases. They may need regular 
growth checks while they take topiramate. 
l) Topiramate may cause birth defects if you take it 
while you are pregnant. If you may become pregnant, 
discuss other possible treatment options with your 
doctor. If a decision is made to take topiramate, use 
effective birth control while you are taking it. Talk 
with your doctor about the best kind of birth control 
to use while taking topiramate, if you are planning to 
become pregnant, and if you have questions or 
concerns about this information. 
m) Pregnancy and Breast-feeding: Topiramate may 
cause birth defects if you take it while you are 
pregnant. If you think you may be pregnant, contact 
your doctor right away. You will need to discuss the 
benefits and risks of taking topiramate while you are 
pregnant. You and your doctor will need to decide if 
you will continue to take topiramate while you are 
pregnant. Topiramate is found in breast milk. If you 
are or will be breast-feeding while you take 
topiramate, check with your doctor. Discuss any 
possible risks to your baby
29-30
. 
CONCLUSION WITH FUTURE PROSPECTIVE: 
Great progress has been made in the last 150 years in the 
pharmacological management of epilepsy, and, despite 
the increasing number of technological advances 
available, antiepileptic drugs (AEDs) remain the 
mainstay of treatment for the vast majority of patients 
with epilepsy. The strengths and weaknesses of those 
AEDs which are currently licensed are examined, and 
ways in which their use may be improved are discussed 
(e.g. rational combinations, use of new formulations). 
Potentially new targets that may allow the development 
of effective treatments are highlighted 
(neuroimmunological manipulation, decreasing inherent 
drug resistance mechanisms, and modification of 
adenosine neurotransmission), and a summary of the 
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most promising AEDs currently in development is 
provide. 
Among some 14 new antiepileptic drugs (AEDs), those 
most extensively tested in humans include topiramate 
(TPM), gabapentin (GBP), lamotrigine (LTG), 
oxcarbazepine (OCBZ), vigabatrin (VGB), and 
zonisamide (ZNS). All are currently marketed in some 
but not all countries. Although no large, comparative 
studies on efficacy have been conducted, all of these 
new AEDs are effective in adult localization-related 
epilepsies, and some have activity in specific syndromes. 
Although these drugs all have some CNS side effects, 
especially when administered in combination with other 
AEDs, they also all have low toxicity profiles.  
Currently information is available for 20 potential anti-
seizure drugs in clinical development. They include 
candidates with mechanisms of action similar to those of 
marketed AEDs (allopregnanolone, brivaracetam, 
ganaxolone, ICA-105665, NS1209, selurampanel); those 
with new mechanisms of action (beprodon, VX-765); 
compounds repurposed for the treatment of epilepsy 
(biperiden, bumetanide, fenfluramine, melatonin, 
nalutozan, pitolisant, quinidine, valnoctamide, 
verapamil). Clinical development of anti-seizure drugs is 
still active but unexciting. Potential anti-seizure drugs 
continue to be largely identified by their activity against 
seizures provoked by electrical or chemical procedures 
in animals with normal brains. As in the past, this may 
lead to new drugs whose efficacy is not better than that 
of those already on the market
31-32
. 
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